Zacks Rating on Opko Health Inc (OPK)

Opko Health Inc (OPK) : The consensus on Opko Health Inc (OPK) based on 4 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Opko Health Inc (OPK) : Currently there are 3 street experts covering Opko Health Inc (OPK) stock. The most bullish and bearish price target for the stock is $20 and $10 respectively for the short term. The average price target of all the analysts comes to $15.67. The estimated standard deviation from the target is $5.13.


Opko Health, Inc. has lost 4.8% in the last five trading days and dropped 4.32% in the last 4 weeks. Opko Health, Inc. has dropped 8.81% during the last 3-month period . Year-to-Date the stock performance stands at -5.27%. Opko Health Inc (NYSE:OPK): On Tuesdays trading session , Opening price of the stock was $9.88 with an intraday high of $9.91. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $9.37. However, the stock managed to close at $9.52, a loss of 2.86% for the day. On the previous day, the stock had closed at $9.8. The total traded volume of the day was 5,377,079 shares.

OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *